Galera Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.13 Insider Own0.60% Shs Outstand26.45M Perf Week36.00%
Market Cap37.49M Forward P/E- EPS next Y-0.71 Insider Trans17.81% Shs Float25.35M Perf Month-16.67%
Income-80.50M PEG- EPS next Q-0.57 Inst Own45.30% Short Float2.55% Perf Quarter-34.11%
Sales- P/S- EPS this Y-4.60% Inst Trans16.83% Short Ratio2.83 Perf Half Y1.19%
Book/sh-2.19 P/B- EPS next Y34.30% ROA-87.60% Target Price12.25 Perf Year-79.01%
Cash/sh3.23 P/C0.53 EPS next 5Y45.70% ROE234.70% 52W Range1.15 - 10.79 Perf YTD-62.96%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.24% Beta-
Dividend %- Quick Ratio6.00 Sales past 5Y- Gross Margin- 52W Low47.83% ATR0.20
Employees30 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)47.50 Volatility17.61% 12.79%
OptionableYes Debt/Eq- EPS Q/Q21.00% Profit Margin- Rel Volume0.50 Prev Close1.69
ShortableYes LT Debt/Eq- EarningsMar 10 BMO Payout- Avg Volume228.32K Price1.70
Recom1.70 SMA201.46% SMA50-17.20% SMA200-56.01% Volume115,824 Change0.59%
Oct-19-21Downgrade BTIG Research Buy → Neutral
Oct-19-21Downgrade BofA Securities Buy → Underperform $17 → $2
Apr-26-21Resumed Credit Suisse Outperform $15
Dec-16-20Upgrade Credit Suisse Neutral → Outperform $9 → $15
Dec-07-20Initiated H.C. Wainwright Buy $15
Dec-02-19Initiated Credit Suisse Neutral
Dec-02-19Initiated Citigroup Buy
Dec-02-19Initiated BTIG Research Buy
Dec-02-19Initiated BofA/Merrill Buy
May-16-22 02:25PM  
May-02-22 07:00AM  
Apr-27-22 10:00AM  
Mar-21-22 06:34PM  
Mar-10-22 07:00AM  
Jan-06-22 07:00AM  
Dec-15-21 08:30AM  
Dec-14-21 01:06PM  
Nov-16-21 09:08AM  
Nov-15-21 07:00AM  
Nov-10-21 07:00AM  
Nov-02-21 09:04AM  
Oct-28-21 07:23AM  
Oct-25-21 02:39PM  
Oct-21-21 12:00PM  
Oct-20-21 10:16AM  
Oct-19-21 12:11PM  
Oct-15-21 08:23AM  
Oct-12-21 07:00AM  
Oct-05-21 02:52PM  
Sep-14-21 07:00AM  
Sep-08-21 07:00AM  
Sep-07-21 07:00AM  
Aug-16-21 08:01AM  
Aug-10-21 07:00AM  
Jun-28-21 07:00AM  
Jun-03-21 04:00AM  
May-26-21 07:00AM  
May-17-21 07:00AM  
May-12-21 04:01PM  
May-11-21 07:00AM  
May-05-21 07:00AM  
Apr-29-21 06:28AM  
Apr-28-21 04:01PM  
Mar-11-21 07:00AM  
Mar-10-21 08:00AM  
Feb-19-21 02:39AM  
Dec-07-20 04:26PM  
Nov-20-20 08:00AM  
Nov-10-20 07:00AM  
Nov-03-20 08:00AM  
Oct-27-20 03:00PM  
Oct-23-20 05:00PM  
Oct-22-20 08:00AM  
Oct-20-20 10:02AM  
Sep-22-20 08:00AM  
Sep-16-20 08:00AM  
Sep-14-20 08:00AM  
Sep-08-20 08:00AM  
Aug-10-20 07:00AM  
Jul-30-20 08:00AM  
Jul-22-20 02:35PM  
Jul-13-20 05:46PM  
Jun-10-20 02:55PM  
May-29-20 08:00AM  
May-18-20 04:05PM  
May-13-20 05:19PM  
May-12-20 07:00AM  
May-05-20 08:00AM  
Apr-30-20 04:15PM  
Apr-02-20 08:00AM  
Mar-10-20 07:00AM  
Feb-27-20 04:05PM  
Feb-24-20 08:00AM  
Feb-19-20 08:00AM  
Jan-07-20 04:40PM  
Dec-17-19 08:00AM  
Dec-10-19 07:00AM  
Dec-05-19 05:18PM  
Dec-02-19 01:10PM  
Nov-06-19 07:26PM  
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Beardsley Robert AChief Operating OfficerDec 17Option Exercise1.0720,00021,40088,191Dec 20 06:30 PM
West LindaDirectorDec 17Buy2.7420,00054,80460,000Dec 20 06:30 PM
HOLMLUND JON TChief Medical OfficerSep 01Option Exercise2.4347,756116,04747,756Sep 03 04:31 PM
HOLMLUND JON TChief Medical OfficerSep 01Sale8.4747,756404,4980Sep 03 04:31 PM
West LindaDirectorJun 15Buy9.1310,00091,30040,000Jun 17 06:41 PM
West LindaDirectorJun 02Buy8.6510,00086,51130,000Jun 04 08:13 PM
Alleva Lawrence MDirectorJun 01Buy8.594,04534,7414,045Jun 03 05:22 PM
West LindaDirectorJun 01Buy8.6410,00086,38120,000Jun 02 05:35 PM
West LindaDirectorMay 28Buy8.6410,00086,41010,000Jun 02 05:35 PM